Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents

Inclusion Criteria: * Male and female children and adolescents between 10 and 17 years, inclusive, preferentially with a primary schizophrenia spectrum diagnosis or bipolar spectrum disorder. * Good physical health as determined by no clinically significant deviation from normal in medical history, clinical laboratory determination, electrocardiograms (ECG) and physical examinations conducted within 14 days prior to study enrollment. * Both the legal guardian and study subject must have signed written informed consent. Consent must have been obtained prior to any screening evaluations. * Subjects must have had a caretaker or guardian who could adequately complete appropriate documentation required by the protocol. Exclusion Criteria: * Sexually active males and females who were not practicing double-barrier birth control, or who were not remaining abstinent, during the study and for 30 days (females only) or 90 days (males only) following the last dose of study medication. * All sexually active females of childbearing potential must have had a negative serum pregnancy test with results available prior to receiving study drug. * Breastfeeding females were excluded. * History of recent (within 6 months) drug or alcohol abuse as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), Diagnostic Criteria for Drug and Alcohol Abuse and/or a positive urine screen for drugs of abuse. * History of mental retardation or mental retardation asse…